Trial Search Results
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
Stanford is currently not accepting patients for this trial.
- Drug: Ponesimod 10 mg
- Drug: Ponesimod 20 mg
- Drug: Ponesimod 40 mg
1. Patients who completed study treatment at their regular Week 24 (End of treatment)
visit within the core study AC-058B201.
2. Signed informed consent for participating in the extension study.
1. Any clinically relevant medical or surgical condition, which, in the opinion of the
investigator, would put the patient at risk by participating in the extension study.
Ages Eligible for Study
18 Years - 55 Years
Genders Eligible for Study